At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 143 enrolled
Drug / intervention
Ipilimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer
In Brief
A Phase 2 clinical trial evaluating Ipilimumab and Best Supportive care (BSC) for Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction. Completed, enrolled 143 participants across 36 sites in 12 countries.
Detailed Summary
The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and gastro-esophageal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Hong Kong, Italy, Japan, Poland, Russia, Singapore, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartJul 2012
Primary CompletionJul 2014
Study CompletionApr 2015
TodayJul 2026
First PostedApr 26, 2012
Enrollment StartJul 1, 2012
Primary CompletionJul 1, 2014
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.2 years ago
Interventions
Ipilimumabbiological
Best Supportive care (BSC)other